|
Development and validation of a gene expression signature based on RB1, PTEN,and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC). |
|
|
Honoraria - BMS; Ipsen; Pfizer |
Consulting or Advisory Role - Eisai |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Merck |
|
|
Research Funding - Janssen (Inst) |
Travel, Accommodations, Expenses - Ipsen; Janssen; Janssen |
|
|
Employment - Reveal Genomics |
|
|
No Relationships to Disclose |
|
Leonardo Rodriguez-Carunchio |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Janssen; Sanofi |
|
|
Honoraria - Astellas, AstraZeneca, Bayer, BMS, MSD, Janssen, Roche, Pfizer, Sanofi |
|
Montserrat Domenech-Santasusana |
Consulting or Advisory Role - Sanofi |
Speakers' Bureau - Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Lilly; Sanofi |
|
|
Consulting or Advisory Role - Ipsen; Pfizer |
Travel, Accommodations, Expenses - Merck |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai Europe; EUSA Pharma; Ipsen; Janssen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Eisai; EUSA Pharma; Janssen Oncology; Janssen-Cilag; Merck; MSD Oncology; Pfizer; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche |
|
|
Honoraria - GlaxoSmithKline; PFIZER; ROCHE; SANOFI |
Consulting or Advisory Role - GlaxoSmithKline; Pfizer; SANOFI |
Research Funding - Janssen; Pfizer |
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst) |
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech |
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche |
|
|
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis Pharmaceuticals UK Ltd.; Pfizer; Roche; Sanofi |
Research Funding - Bayer; Janssen; Roche |
Travel, Accommodations, Expenses - Janssen; Pfizer |